Edwards Lifesciences' ROE Fuels Long-Term Growth Amidst Recent Stock Decline.

Edwards Lifesciences' stock has declined 4.7% in the past month, but its financial indicators look decent. The company's return on equity (ROE) is 13%, which compares favorably to the industry average of 9.8%. However, Edwards Lifesciences has posted only 4.6% growth over the past five years, despite its high ROE. The company may have a high payout ratio or poor capital allocation, which could explain this discrepancy.